Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Signs or symptoms of decompensated liver disease such as variceal bleeding, ascites, hepatic encephalopathy, active jaundice defined by an indirect bilirubin \> 2, Alanine transaminase (ALT) or Aspartate aminotransferase (AST) laboratory values ≥ 10 times the upper limit of normal, or other evidence of decompensated liver disease, or hepatocellular carcinoma

Chronic liver disease other than HCV not limited to Hepatitis B virus (HBV) \[positive test for hepatitis B surface antigen (HBsAg)\], hemochromatosis, auto-immune hepatitis, alcoholic liver disease or non-alcoholic fatty liver disease

History of liver transplantation

Co-infection with Human immunodeficiency virus (HIV) \[positive test for anti-HIV Ab\] or use of didanosine

History of a heart attack, cardiac ischemia, heart disease, clinically symptomatic cardiac abnormalities, or blood clots, based on medical history or apparent on physical exam

QTcF interval at Visit 1 of greater than or equal to 450 ms by Fridericia's correction, or a personal or family history of Torsades de Pointe

History or presence of sarcoidosis or pancreatitis

History or presence of severe pulmonary function impairment including severe (\> GOLD stage III) chronic obstructive pulmonary obstructive disease, and moderate to severe asthma

Uncontrolled diabetes mellitus as evidenced by HbA1C ≥ 8.5% at screening (Visit 1)

Use of the following medications concurrently or within the 30 days prior to Screening (Visit 1) associated with QT prolongation: macrolides, antiarrhythmic agents, azoles, fluoroquinolones, and tricyclic anti-depressants (specifically excluded medication will be listed in protocol Section 6.8)

Use of immunosuppressive or immune-modulating agents (including azathioprine, corticosteroids and immunosuppressive agents) or presence of an immunologically-mediated autoimmune disease (other than asthma) or history of solid organ or bone marrow transplantation (note: inhaled steroids for mild/moderate asthma and topical steroid for minor skin conditions allowed and washout period for per Oral (PO)/Intramuscular (IM)/ Intravenous (IV) corticosteroid use is 8 weeks; washout periods for other immunosuppressives determined by Medical Monitor)

Use of strong CYP3A4-inhibiting protease inhibitors (specifically Atazanavir, Indinavir, Nelfinavir, Saquinavir, and Ritonavir), strong CYP3A4 inhibitors (specifically Clarithromycin, Itraconazole, Ketoconazole, Nefazodone, Telithromycin), or strong CYP3A4 inducers (specifically Rifampin, Efavirenz, Etravirine, Phenobarbital, Phenytoin, and Carbamazepine)

Absolute neutrophil count of \< 1800 cells/mm3, or platelet count \< 130,000 cells/mm3, or hemoglobin \< 12 g/dl for women and \< 13 g/dl for men, or a history of anemia, sickle cell anemia, or thalassemia; (note: if baseline value within 5% of minimum qualifying value, one re-test allowed for the purpose of qualifying for study)

A history or presence of abnormal thyroid function that is not adequately controlled \[defined as Thyroid-stimulating hormone (TSH) levels less than 0.8 x lower limit of normal (LLN) or greater than 1.2 x the upper limit of normal (ULN)\]

Creatinine clearance \< 50 mL/minute, serum creatinine concentration ≥ 1.5 times the ULN, or albumin ≤ 3 g/dl

Presence or history of bipolar disorder, schizophrenia, psychosis, or unstable psychiatric condition, or hospitalization for psychiatric condition, or suicide attempt. (Note: Subjects with psychiatric conditions need to be adequately treated and on stable doses of appropriate medications for at least 3 months prior to Visit 1. History of suicidal ideation within prior 3 months is exclusionary)

Any malignancy within the last 5 years other than treated cervical carcinoma in situ or treated basal cell carcinoma with no more than 20% risk of recurrence within 2 years

Alcohol abuse by the assessment of the investigator within the past 2 years or an alcohol use pattern that will interfere with the study conduct

Drug abuse by the assessment of the investigator within the last six months

Pregnancy, current lactation in female subjects, or male subjects with partners who are pregnant, or females intending to become pregnant

Major surgery within 30 days prior to Visit 1

Participation in another clinical trial of an investigational drug or device within 6 months prior to Visit 1 unless that prior participation involved exposure only to placebo by clear and available documentation

Donation of blood or plasma within 30 days prior to Visit 1 (not including routine laboratory assessments)

What this study is about